Administration of ondansetron is associated with lethal outcome

Pediatrics

Volumn 125, Issue 6, 2010, Pages

  Gener, Blanca ^a   Burns, Jarrett M ^b   Griffin, Susanne ^b   Boyer, Edward W ^b  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Malignant hyperthermia; Ondansetron; Pediatric; Sepsis; Serotonin syndrome

Indexed keywords

ADRENALIN; BICARBONATE; GLUCONATE CALCIUM; GLUCOSE; INSULIN; ONDANSETRON;

ABDOMINAL PAIN; ADVERSE OUTCOME; ARTICLE; CASE REPORT; CHILD; ECHO VIRUS; ECHOVIRUS INFECTION; ENDOTRACHEAL INTUBATION; GENE MUTATION; GENETIC VARIABILITY; HEART VENTRICLE TACHYCARDIA; HOST SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; HYPERTHERMIA; LABORATORY TEST; MALE; MULTIMINICORE DISEASE; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESUSCITATION; VOMITING;

ANTIEMETICS; CHILD, PRESCHOOL; DISEASES IN TWINS; FATAL OUTCOME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MYOPATHIES, STRUCTURAL, CONGENITAL; ONDANSETRON; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TRIPLETS; TWINS, MONOZYGOTIC; VOMITING;

EID: 77953059019     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-2795     Document Type: Article

References (17)

1. Pfeil N, Uhlig U, Kostev K, et al. Antiemetic medications in children with presumed infectious gastroenteritis: pharmacoepidemiology in Europe and Northern America. J Pediatr. 2008;153(5):659-662
2. Alhashimi D, Alhashimi H, Fedorowicz Z. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2006;(3):CD005506
3. Cubeddu LX, Trujillo LM, Talmaciu I, et al. Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther. 1997;11(1):185-191
4. Freedman SB, Adler M, Seshardri R, Powel EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354(16):1698-1705
5. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002;39(4):397-403 (Pubitemid 34263493)
6. Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. Pediatrics. 2002;109(4). Available at: www.pediatrics.org/cgi/content/full/109/ 4/e62
7. Szajewska H, Gieruszczak-Bialek D, Dylag M. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007;25(4):393-400 (Pubitemid 46184452)
8. Stork CM, Brown KM, Reilly TH, Secreti L, Brown LH. Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. Acad Emerg Med. 2006;13(10):1027-1033 (Pubitemid 44430160)
9. George M, Al-Duaij N, O'Donnell KA, Shannon MW. Obtundation and seizure following ondansetron overdose in an infant. Clin Toxicol (Phila). 2008;46(10):1064-1066
10. Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT3 antagonist agents. Psychosomatics. 2001;42(3):258-260
11. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120
12. 2 receptor agonist on anaesthetized pigs susceptible to malignant hyperthermia. Br J Anaesth. 2003;91(2):281-284
13. Wappler F, Roewer N, Kochling A, et al. Effects of the serotonin sub 2 receptor agonist DOI on skeletal muscle specimens from malignant-hyperthermia- susceptible patients. Anesthesiology. 1996;84(6):1280-1287 (Pubitemid 26192034)
14. Koch BM, Bertorini TE, Eng GD, Boehm R. Severe multicore disease associated with reaction to anaesthesia. Arch Neurol. 1985;42(12):1204-1206
15. Osada H, Masuda K, Seki K, Sekiya S. Multi-minicore disease with susceptibility to malignant hyperthermia in pregnancy. Gynecol Obstet Invest. 2004;58(1):32-35
16. Jungbluth H. Multiminicore disease. Orphanet J Rare Dis. 2007;2:31
17. Zofran (ondansetron hydrochloride) [tablet prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2006